Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04333953 · ClinicalTrials.gov registry record
COVID-19 in Patients With HIV
A clinical trial of COVID-19 and HIV/AIDS, sponsored by University of Missouri-Columbia.
- Completed
- Registry status
- 412
- Enrollment target
- 1
- Study location
NCT04333953: Completed study of COVID-19 and HIV/AIDS, sponsored by University of Missouri-Columbia.
NCT04333953 is a study of COVID-19 and HIV/AIDS that has completed, run by University of Missouri-Columbia. The registered enrollment target is 412 participants, below the 38,464-participant average among 298 other COVID-19 trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04333953, a study of COVID-19 and HIV/AIDS, has completed, sponsored by University of Missouri-Columbia.
- COMPLETED
- Registry status
- 412 participants
- Enrollment target
- 1
- Study location
Study Summary
Currently, limited data is available about patients with HIV in the context of the COVID-19 pandemic. People with HIV who have not achieved viral suppression through antiretroviral treatment may have a compromised immune system that leaves them vulnerable to infections and disease progression. However, little is known about the presentation and clinical outcomes of patients with HIV and SARS-CoV-2. Our aim is to characterize the clinical presentation and disease course of COVID-19 in patients with HIV.
Primary Outcome
COVID-19 related death among patients with HIV and COVID-19
Conditions Studied
Interventions
- OTHER No intervention
Study Locations (1)
Missouri
- University of Missouri-Columbia - Columbia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 412 participants |
| Start Date | 2020-04-01 |
| Est. Completion | 2022-03-28 |
What the finished NCT04333953 record still lists
NCT04333953 is an observational study that tracks outcomes without assigning an intervention. The registered 412 participants enrollment target is mid-sized for trials with a published cap, below the 38,464-participant average among 298 other COVID-19 trials with a reported enrollment target (99% lower).
The record links to 3 conditions, with COVID-19 appearing as the primary indexed condition, and to 1 intervention - of which No intervention is the first listed.
NCT04333953 reports a single indexed study location in Missouri.
Frequently Asked Questions
What is clinical trial NCT04333953 about?
NCT04333953 is a clinical study titled "COVID-19 in Patients With HIV". Currently, limited data is available about patients with HIV in the context of the COVID-19 pandemic. People with HIV who have not achieved viral suppression through antiretroviral treatment may have a compromised immune system that leaves them vulnerable to infections and disease progression. Howev...
What is the current status of trial NCT04333953?
This trial is currently completed. The enrollment target is 412 participants. The study started on 2020-04-01. Estimated completion is 2022-03-28.
What conditions does trial NCT04333953 study?
This clinical trial studies the following conditions: COVID-19, HIV/AIDS, SARS-CoV-2.
What interventions are being tested in trial NCT04333953?
The interventions under investigation include: No intervention (OTHER).
Who is sponsoring clinical trial NCT04333953?
This trial is sponsored by University of Missouri-Columbia, which has 291 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04333953 being conducted?
This trial has 1 study location across Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for COVID-19
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04333953's enrollment target sits among peer trials
412 121st of 298 higher than 177 of 298 other COVID-19 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other COVID-19 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
CArdiac REhabilitation for Building Exertional heArt Rate for Chronotropic Incompetence in Long COVID-19
RECRUITING · NA
-
Arginine Replacement Therapy in COVID-19
RECRUITING · Phase 2
-
A Study to Learn About Variant-Adapted COVID-19 RNA Vaccine Candidate(s) in Healthy Children
RECRUITING · Phase 2
-
Cardiac Magnetic Resonance Tissue Characterization in COVID-19 Survivors
RECRUITING
-
COVID-19 Health Adjustments in Nutrition, General Wellness, and Exercise
RECRUITING
-
The Impact of COVID-19 on Maternal and Neonatal Outcomes
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05993689 · 412 participants · NA
Building TrUst and UNiting Teams Through DouLa partnErship - BUNDLE
- NCT06699212 · 412 participants · Phase 3
A Study of ASP-1929 Photoimmunotherapy in Combination With Pembrolizumab in First-line Treatment of Locoregional Recurrent Squamous Cell Carcinoma of the Head and Neck With No Distant Metastases
- NCT03592472 · 413 participants · Phase 3
A Study of Pazopanib With or Without Abexinostat in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma (RENAVIV)
- NCT06697197 · 413 participants · Phase 1
A Study of BMS-986482 Alone or as Combination Therapy in Participants With Advanced Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI